{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=33", "query": { "intervention": "Safety Control", "page": 33 }, "page_size": 10 }, "pagination": { "page": 33, "page_size": 10, "total_count": 14119, "total_pages": 1412, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=34&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=32&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T02:04:45.838Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00313300", "title": "Safety Study of Apixaban in Recent Acute Coronary Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Coronary Syndrome (ACS)" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 1741, "start_date": "2006-05", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2015-12-30", "last_synced_at": "2026-11-03T02:04:45.838Z", "location_count": 30, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Santa Rosa, California + 27 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Lakeland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00313300" }, { "nct_id": "NCT03771664", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder", "Insomnia" ], "interventions": [ { "name": "SAGE-217", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 87, "start_date": "2019-02-04", "completion_date": "2020-01-17", "has_results": true, "last_update_posted_date": "2023-11-29", "last_synced_at": "2026-11-03T02:04:45.838Z", "location_count": 28, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 24 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Garden Grove", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03771664" }, { "nct_id": "NCT01356849", "title": "Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Disease", "Diabetic Nephropathy" ], "interventions": [ { "name": "Atrasentan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2011-04", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2013-08-28", "last_synced_at": "2026-11-03T02:04:45.838Z", "location_count": 59, "location_summary": "Pell City, Alabama • Tempe, Arizona • Azusa, California + 48 more", "locations": [ { "city": "Pell City", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Azusa", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01356849" }, { "nct_id": "NCT05153148", "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "NDI-034858", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 305, "start_date": "2022-01-06", "completion_date": "2023-06-02", "has_results": true, "last_update_posted_date": "2024-05-31", "last_synced_at": "2026-11-03T02:04:45.838Z", "location_count": 23, "location_summary": "Palm Desert, California • Upland, California • Hollywood, Florida + 19 more", "locations": [ { "city": "Palm Desert", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05153148" }, { "nct_id": "NCT05923099", "title": "A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "LEO 138559", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 262, "start_date": "2023-09-20", "completion_date": "2025-04-09", "has_results": true, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-11-03T02:04:45.838Z", "location_count": 12, "location_summary": "Fountain Valley, California • Los Angeles, California • San Francisco, California + 9 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05923099" }, { "nct_id": "NCT02569398", "title": "An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Asymptomatic Amyloid-positive" ], "interventions": [ { "name": "Atabecestat, 5 mg", "type": "DRUG" }, { "name": "Atabecestat, 25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "60 Years to 85 Years" }, "enrollment_count": 557, "start_date": "2015-10-29", "completion_date": "2018-12-20", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-11-03T02:04:45.838Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Downey", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02569398" }, { "nct_id": "NCT05352893", "title": "Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Generalized Pustular Psoriasis" ], "interventions": [ { "name": "750 mg Imsidolimab", "type": "DRUG" }, { "name": "300 mg Imsidolimab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vanda Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 45, "start_date": "2022-04-14", "completion_date": "2023-08-17", "has_results": true, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-11-03T02:04:45.838Z", "location_count": 5, "location_summary": "Largo, Florida • Louisville, Kentucky • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Largo", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" }, { "city": "Springville", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05352893" }, { "nct_id": "NCT04040816", "title": "Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gout", "Hyperuricemia" ], "interventions": [ { "name": "SAP-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanton Pharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 40, "start_date": "2019-01-01", "completion_date": "2020-08-30", "has_results": false, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-11-03T02:04:45.838Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Anaheim, California • South Miami, Florida + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "South Miami", "state": "Florida" }, { "city": "Meridian", "state": "Idaho" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04040816" }, { "nct_id": "NCT00603616", "title": "Induction of Clinical Response Using Rifaximin in Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Placebo Comparator", "type": "DRUG" }, { "name": "Rifaximin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Scott Lee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 36, "start_date": "2008-11", "completion_date": "2020-11-03", "has_results": false, "last_update_posted_date": "2021-12-09", "last_synced_at": "2026-11-03T02:04:45.838Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00603616" }, { "nct_id": "NCT00412984", "title": "Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Atrial Flutter" ], "interventions": [ { "name": "warfarin", "type": "DRUG" }, { "name": "apixaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20976, "start_date": "2006-12-31", "completion_date": "2011-05-25", "has_results": true, "last_update_posted_date": "2018-07-03", "last_synced_at": "2026-11-03T02:04:45.838Z", "location_count": 284, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 206 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00412984" } ] }